Catalyst
Slingshot members are tracking this event:
FDA Accepts Novartis' (NVS) Supplemental New Drug Application (sNDA) Under Priority Review for Zykadia (Ceritinib) in First-Line Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Supplemental New Drug Application, Snda, Priority Review, Zykadia, Ceritinib, First-line Treatment, Metastatic, Alk-positive, Non-small Cell Lung Cancer, Nsclc
